Researchers will assess how the immune system goes wrong in dogs with IMHA, and the team will study how individual dogs respond to medications available for treatment.
Researchers will develop and validate a novel molecular tool to assess residual cancer cell levels in dogs with aggressive T-cell lymphoma to help improve treatment and disease monitoring.